U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06854094) titled 'Consolidation Therapy with Cladribine in Relapsing Multiple Sclerosis Patients' on Feb. 25.
Brief Summary: To investigate the impact on IgG and IgM concentration, infection risk and effectiveness of switching from anti-CD20 to cladribine compared to continued anti-CD20 treatment over 2 years in relapsing MS patients.
Study Start Date: Oct. 03, 2024
Study Type: OBSERVATIONAL
Condition:
Multiple Sclerosis
Recruitment Status: RECRUITING
Sponsor: Ente Ospedaliero Cantonale, Bellinzona
Information provided by (Responsible Party): Chiara Zecca, Ente Ospedaliero Cantonale, Bellinzona
Published by HT Digital Content Services with pe...